Praxis Capital set to invest $220 mln in Fresheasy The PE firm hopes to capitalize on rapid growth in the HMR sector
Translated by Soin Kim 공개 2021-03-17 08:52:25
이 기사는 2021년 03월 17일 08:06 thebell 에 표출된 기사입니다.
Praxis Capital plans to invest in South Korea’s largest meal kit company Fresheasy, hoping to create synergy with its existing portfolio companies.The private equity (PE) firm will inject 250 billion won ($220 million) to 300 billion won of new capital into Fresheasy, which will make it the largest shareholder in the company. The investment will be partly financed through the firm's blind-pool fund, Praxis Value Creation Fund II, which was closed at 490 billion won in 2020.
Praxis Capital has targeted companies in the home meal replacement (HMR) sector to capitalize on the market’s high growth potential. The South Korean HMR market has grown at an annual growth rate of nearly 20% in recent years, and is expected to grow to 7 trillion won by 2022 from 4 trillion won in 2020.
Founded in 2016, Fresheasy is the largest meal kit company in the country with a market share of 70%. Its revenue has grown exponentially in recent years, increasing to 71.1 billion won in 2019 from 21.8 billion won in 2018. Its 2020 revenue is believed to have more than doubled year-on-year.
Fresheasy has raised more than 100 billion won to date through three rounds of fundraising since 2018. It received 30 billion won from Hana Financial Investment Private Equity and GS Home Shopping in early 2019.
In 2019, the company also raised 50 billion won from nine investors including SoftBank Ventures Asia, NAU IB Capital, NongHyup Bank, NH Investment & Securities, SBI Investment, Union Investment Partners, Industrial Bank of Korea, Korea Investment & Securities and GS Home Shopping in a funding round that valued the company at around 160 billion won. The proceeds were used to build a new plant in Yongin, Gyeonggi province. (Reporting by Si-eun Park)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [제일약품의 온코닉테라퓨틱 첫 '신약']세번째 P-CAB '자큐보' 2년만에 신약 명맥 잇는다
- 강동그룹, 디아너스CC 품는다
- [제약사 TSR 분석]제일약품, '주가·실적·배당' 3중고 열쇠 '온코닉의 신약'
- (여자)아이들 우기, 'YUQ1' 아이튠즈 앨범차트 10개국 석권
- 박셀바이오, 진행성 간세포암 타깃 'Vax-NK' 특허 출원
- 베니스 비엔날레, 30년만에 두발로 선 '곽훈'의 의미
- [대기업 프로스포츠 전술전략]'모기업발 숙제' 엔씨다이노스, 당분간 긴축 불가피
- 하이브, '민희진 없는' 어도어 경쟁력 입증할까
- SK 오너가 3세 최성환의 '승부수'
- 어느 수집가의 꿈 '이건희 컬렉션'